- Conditions
- Eldery People, Cognitive Decline, Memory Decline, DHA CNS Delivery
- Interventions
- LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)
- Dietary Supplement
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 55 Years to 82 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced May 22, 2026, 5:44 AM EDT